ATE297941T1 - Verfahren zur herstellung von einer kristallinen form ii von clarythromycin - Google Patents

Verfahren zur herstellung von einer kristallinen form ii von clarythromycin

Info

Publication number
ATE297941T1
ATE297941T1 AT01106198T AT01106198T ATE297941T1 AT E297941 T1 ATE297941 T1 AT E297941T1 AT 01106198 T AT01106198 T AT 01106198T AT 01106198 T AT01106198 T AT 01106198T AT E297941 T1 ATE297941 T1 AT E297941T1
Authority
AT
Austria
Prior art keywords
clarithromycin
water
trimethylsilyl
oxime
group
Prior art date
Application number
AT01106198T
Other languages
English (en)
Inventor
Kwee-Hyun Suh
Sang-Min Yun
Mi-Ra Seong
Gi-Jeong Kim
Gwan-Sun Lee
Nam-Du Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020000013033A external-priority patent/KR100361397B1/ko
Priority claimed from KR10-2000-0069834A external-priority patent/KR100367981B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of ATE297941T1 publication Critical patent/ATE297941T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01106198T 2000-03-15 2001-03-14 Verfahren zur herstellung von einer kristallinen form ii von clarythromycin ATE297941T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020000013033A KR100361397B1 (ko) 2000-03-15 2000-03-15 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
KR10-2000-0069834A KR100367981B1 (ko) 2000-11-23 2000-11-23 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물

Publications (1)

Publication Number Publication Date
ATE297941T1 true ATE297941T1 (de) 2005-07-15

Family

ID=36274127

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04013295T ATE338053T1 (de) 2000-03-15 2001-03-14 Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität
AT01106198T ATE297941T1 (de) 2000-03-15 2001-03-14 Verfahren zur herstellung von einer kristallinen form ii von clarythromycin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04013295T ATE338053T1 (de) 2000-03-15 2001-03-14 Verfahren zur herstellung von clarythromycin mit nicht pharmazeutischer qualität

Country Status (15)

Country Link
US (1) US6515116B2 (de)
EP (2) EP1469008B1 (de)
JP (1) JP4119125B2 (de)
CN (1) CN1193036C (de)
AT (2) ATE338053T1 (de)
AU (1) AU771825B2 (de)
BR (1) BR0109194A (de)
CA (1) CA2402201C (de)
DE (2) DE60111438T2 (de)
ES (2) ES2270226T3 (de)
HU (1) HUP0300418A3 (de)
MX (1) MXPA02008861A (de)
NZ (1) NZ521184A (de)
RU (1) RU2230748C2 (de)
WO (1) WO2001068662A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
CA2801100A1 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Macrolides and processes for their preparation
ES2221807B1 (es) * 2003-06-24 2005-12-16 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (de) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
WO2006081711A1 (fr) * 2005-02-07 2006-08-10 Zte Corporation Méthode de contrôle de mesure entre systèmes et mesure entre fréquences
WO2007015265A2 (en) * 2005-05-24 2007-02-08 Kopran Research Laboratories Ltd A process for preparing 6,9-imino ether
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (de) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
EP2214484A4 (de) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Verfahren zur herstellung von antibakteriellen makrolid-wirkstoffen
SI2358379T1 (sl) * 2008-10-24 2016-05-31 Cempra Pharmaceuticals, Inc. Postopki biološke obrambe z makrolidi, ki vsebujejo triazol
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
RU2650883C2 (ru) 2010-03-22 2018-04-18 Семпра Фармасьютикалз, Инк. Кристаллические формы макролида и их применение
EP2571506B1 (de) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Verfahren zur herstellung von makroliden und ketoliden sowie zwischenprodukte dafür
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
IN2014DN08939A (de) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN103897002A (zh) * 2012-12-31 2014-07-02 菏泽市方明制药有限公司 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法
EP2968801B1 (de) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Verfahren zur behandlung von atemwegserkrankungen und formulierungen dafür
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) * 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
DE29724846U1 (de) * 1996-07-29 2004-12-16 Abbott Laboratories, Abbott Park Herstellung von kristalliner Form II von Clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) * 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US6258785B1 (en) * 1998-12-02 2001-07-10 Pfizer Inc. Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin

Also Published As

Publication number Publication date
JP2004500398A (ja) 2004-01-08
ES2270226T3 (es) 2007-04-01
WO2001068662A1 (en) 2001-09-20
RU2230748C2 (ru) 2004-06-20
EP1134229A3 (de) 2002-02-27
HUP0300418A2 (hu) 2003-06-28
CN1429233A (zh) 2003-07-09
CA2402201C (en) 2007-06-05
CN1193036C (zh) 2005-03-16
CA2402201A1 (en) 2001-09-20
HUP0300418A3 (en) 2003-09-29
AU771825B2 (en) 2004-04-01
JP4119125B2 (ja) 2008-07-16
AU4282701A (en) 2001-09-24
EP1469008B1 (de) 2006-08-30
EP1134229A2 (de) 2001-09-19
EP1469008A1 (de) 2004-10-20
US20010039333A1 (en) 2001-11-08
DE60122791D1 (de) 2006-10-12
ES2242668T3 (es) 2005-11-16
BR0109194A (pt) 2003-02-11
EP1134229B1 (de) 2005-06-15
RU2002127591A (ru) 2004-02-27
DE60111438D1 (de) 2005-07-21
MXPA02008861A (es) 2003-02-10
DE60122791T2 (de) 2007-10-04
NZ521184A (en) 2004-02-27
US6515116B2 (en) 2003-02-04
ATE338053T1 (de) 2006-09-15
DE60111438T2 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE297941T1 (de) Verfahren zur herstellung von einer kristallinen form ii von clarythromycin
ATE232211T1 (de) Verfahren zur herstellung von form ii kristallen des clarithromycins
CA2386221A1 (en) Compounds for protecting hydroxyls and methods for their use
CA2327775C (en) 15-membered lactams ketolides with antibacterial activity
DE69836697T2 (de) Neue 3,6-Hemiketale der 9a-Azalidklasse
HUP0104600A2 (hu) Új intermedierek és eljárás azokból makrolid antibiotikum előállítására
CA1178596A (en) 4"-epi erythromycin a and derivatives thereof as useful antibacterial agents
KR880007740A (ko) 마크롤리드 화합물, 그의 제법 및 그의 용도
ATE309262T1 (de) Verfahren zur herstellung von aufgereinigtem anthocyanin und kristallines anthocyanin
DE60029439T2 (de) Neue 8a- und 9a-lactame mit 15 ringatomen
WO2002018403A1 (fr) Procede permettant la production d'un derive d'erythromycine
EP0262905A2 (de) Modifizierungen in 3-0-Demethyl-Mycinose in Macrocin und Lactenocin
SK286243B6 (sk) Dve polymorfné formy difosfátovej soli 4''-substituovaného-9- deoxo-9-aza-9a-homo-erytromycínového derivátu, spôsob ich prípravy, čistenie a použitie, farmaceutické kompozície s ich obsahom
ATE238331T1 (de) Neue hydroxyderivate von tylosin und verfahren zu deren herstellung
IE820576L (en) Preparing a mononucleoside-3'-phosphodiester-based substrate
DE69704778T2 (de) Verfahren zur herstellung von salzen von erythromicyn, roxithromicyn, clarythromicyn und azithromycin
EP1444244B1 (de) Verfahren zur herstellung von desclarithromycin, sowie zwischenprodukte
DD271332A1 (de) Verfahren zur herstellung von ribonucleotiden
JPS55115898A (en) 3",4"-diacyltylosin derivative
MXPA00009875A (es) Cetolidos de lactamas de 15 miembros con actividad antibacteriana
WO2006087238B1 (en) Method for the production of macrolides
EP0972778A1 (de) Erythromycin A Derivate und Verfahren zu deren Herstellung
MXPA00004863A (en) Process for n-desmethylating erythromycins and derivatives thereof
DE3308563A1 (de) 3-epistreptomycin und sein dihydroderivat, verfahren zu deren herstellung und diese enthaltende zusammensetzung
DE69605520T2 (de) Natrium-Orthohydroxymandelat-Phenol-Wasser-Komplexe, Verfahren zu deren Herstellung sowie Verwendung zur Isolation des Natrium Orthohydroxymandelats

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties